Recombinant Human BRD2 Protein，His

BRD2 (Bromodomain containing 2) is a member of the bromodomain and extraterminal (BET) protein family, which plays a crucial role in regulating gene expression through interaction with acetylated lysine residues on histones and non-histone proteins. This interaction is vital for various cellular processes, including transcriptional regulation, cell cycle progression, and differentiation. Dysregulation of BRD2 has been implicated in several diseases, notably cancer and inflammatory disorders. Studies have shown that BRD2 can influence the expression of oncogenes, thereby contributing to tumorigenesis. Due to its pivotal role in epigenetic regulation, BRD2 has emerged as a promising therapeutic target. Researchers are increasingly focusing on the development of BRD2 inhibitors to explore their potential in cancer treatment. Moreover, the production of recombinant BRD2 proteins is essential for elucidating its molecular mechanisms and interactions. By employing advanced protein expression systems, scientists aim to generate highly pure and functional BRD2 proteins that can be used in biochemical assays, structural studies, and drug discovery efforts. Understanding the structure-function relationship of BRD2 will facilitate the identification of specific inhibitors and enhance our overall comprehension of its role in health and disease. Thus, the study of BRD2, particularly through the lens of recombinant protein research, is crucial for advancing therapeutic strategies aimed at modulating its activity in various pathological conditions.